1. Home
  2. EARN vs CMPX Comparison

EARN vs CMPX Comparison

Compare EARN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

N/A

Current Price

$5.17

Market Cap

189.7M

Sector

Real Estate

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

N/A

Current Price

$4.95

Market Cap

752.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EARN
CMPX
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
752.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
EARN
CMPX
Price
$5.17
$4.95
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$5.88
$13.44
AVG Volume (30 Days)
318.9K
1.8M
Earning Date
11-19-2025
11-05-2025
Dividend Yield
18.57%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
N/A
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$1.33
52 Week High
$6.86
$5.86

Technical Indicators

Market Signals
Indicator
EARN
CMPX
Relative Strength Index (RSI) 44.61 48.47
Support Level $5.10 $5.09
Resistance Level $5.20 $5.32
Average True Range (ATR) 0.09 0.35
MACD -0.02 -0.08
Stochastic Oscillator 13.75 10.68

Price Performance

Historical Comparison
EARN
CMPX

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: